ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Chinese National Intellectual Property Administration has issued two new patents to ENDRA, Chinese Patent No. ZL 2020 8 00151255 (the ‘255 patent) titled “Systems and Methods for Thermoacoustic Transducer Optimization” and Chinese Patent No. ZL 2020 8 00151433 (the ‘433 patent) titled “Method and System for Reconstructing a Thermoacoustic Image.”
“We are delighted to announce our 14th and 15th issued patents in China, which provide intellectual property protection through 2040. These patents demonstrate our commitment to protecting the novel technology used in our TAEUS System in Asia’s largest healthcare market with an estimated 350 million people affected by NAFLD-NASH," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "Our global intellectual property portfolio has increased to 50 issued patents as we expand protection of our core technology in priority global markets.”
The ‘255 patent relates to characterizing a given system by placing a small, high-contrast object called an impulse in a field of view, and using the resulting impulse data to optimize transducer functionality. Examples of transducer functionality are transducer geometry, an arrangement of transducer elements and a distribution of transducer elements. The ‘255 parent patent is U.S. Patent No. 10993624. The ‘433 patent utilizes a view and position-specific kernel to correct for differences in the relative relationship between a transducer element array and an object within a region of interest to be imaged. The ‘433 parent patent is U.S. Patent No. 10687789.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.